COMPANY
Clinical Phase 2
Location: El Monte, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Keywords: Head and Neck Squamous Cell Carcinoma FID-022 FID007
Timeline
- Trial start Phase 1: Study of FID-022 in Participants With Advanced Solid Tumors source ↗
- Trial start Phase 2: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma source ↗
Upcoming milestones
- Dec 31, 2027 (ESTIMATED) · Phase 1 · Study of FID-022 in Participants With Advanced Solid Tumors · NCT06694480
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT06694480 | Study of FID-022 in Participants With Advanced Solid Tumors | Phase 1 | Recruiting | Jul 3, 2025 | Dec 31, 2027 (estimated) |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Active, not recruiting | Apr 10, 2024 | Dec 31, 2025 (actual) |
